Cenicriviroc is an investigational small molecule acting as a dual CCR2 and CCR5 antagonist, under evaluation for its potential in treating HIV-1 infection and non-alcoholic steatohepatitis. Analytical… Read more
Cenicriviroc is an investigational small molecule acting as a dual CCR2 and CCR5 antagonist, under evaluation for its potential in treating HIV-1 infection and non-alcoholic steatohepatitis. Analytical laboratories require high-quality reference standards for cenicriviroc to support rigorous method development and validation protocols. This category provides access to the parent drug, its known metabolites, such as cenicriviroc sulfone, and degradation products like N-nitroso cenicriviroc. These materials are essential for impurity profiling and ensuring accuracy during stability testing. Additionally, stable isotope labelled compounds, including various deuterated analogs, serve as critical internal standards for mass spectrometry-based quantitative bioanalysis. Utilizing these characterized compounds allows researchers to precisely track the drug and its related substances throughout pharmaceutical research, clinical trials, and quality control assays, facilitating adherence to regulatory standards during the drug development lifecycle.